PMID- 30815823
OWN - NLM
STAT- MEDLINE
DCOM- 20200207
LR  - 20200309
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 64
IP  - 8
DP  - 2019 Aug
TI  - Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not 
      Associated with Anemia in the Infant.
PG  - 2286-2290
LID - 10.1007/s10620-019-05555-0 [doi]
AB  - INTRODUCTION: Thiopurine exposure throughout pregnancy in patients with 
      inflammatory bowel diseases (IBD) is common and teratogenically safe. Late 
      consequences of in utero exposure to thiopurines and its metabolite, 
      6-thioguanine nucleotides (6-TGN), such as neonatal and infant anemia are still 
      disputed. AIM: To evaluate whether 6-TGN exposure during pregnancy influences 
      anemia in infants at 1 year of life. METHODS: A comparative observational study 
      was performed between 2009 and 2015 at a multidisciplinary IBD clinic dedicated 
      to pregnant women. The hemoglobin level and signs of anemia between 9 and 
      15 months after birth of infants born to women exposed to thiopurines throughout 
      the entire pregnancy was compared to infants of women with no thiopurine exposure 
      during pregnancy. RESULTS: Altogether, 34 patients, 21 in the study group and 13 
      in the control group, were included. The median duration of maternal thiopurine 
      exposure prior to pregnancy was 24 months (range 12-72 months), and median dosage 
      was 100 mg (range 50-175 mg). Maternal IBD activity, infants' iron 
      supplementation, and iron deficiency diagnoses were similar between both groups. 
      The infants' mean hemoglobin level (gr/dL) in the thiopurine-exposed women versus 
      the control group was 11.48 +/- 0.8 versus 11.54 +/- 0.6, respectively, p = 0.81. The 
      composite risk of any sign of infant anemia was numerically higher in the 
      thiopurine-exposed women, 10 (47%), compared to non-exposed women, 3 (23%), 
      p = 0.17. The mean corpuscular volume, red cell distribution width, white blood 
      cell, and platelet counts were similar among groups. CONCLUSIONS: Thiopurine 
      therapy during pregnancy in women with IBD is safe for long-term neonatal 
      outcomes; still large-scale confirmatory studies are required.
FAU - Koslowsky, Benjamin
AU  - Koslowsky B
AUID- ORCID: 0000-0002-6935-6051
AD  - Digestive Diseases Institute, Shaare Zedek Medical Center, 12 Bayit St., 91031, 
      Jerusalem, Israel. binyaminkos@szmc.org.il.
FAU - Sadeh, Chen
AU  - Sadeh C
AD  - Digestive Diseases Institute, Shaare Zedek Medical Center, 12 Bayit St., 91031, 
      Jerusalem, Israel.
FAU - Grisaru-Granovsky, Sorina
AU  - Grisaru-Granovsky S
AD  - Fetal-Maternal Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
FAU - Miskin, Hagit
AU  - Miskin H
AD  - Pediatric Hematology Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
FAU - Goldin, Eran
AU  - Goldin E
AD  - Digestive Diseases Institute, Shaare Zedek Medical Center, 12 Bayit St., 91031, 
      Jerusalem, Israel.
FAU - Bar-Gil Shitrit, Ariella
AU  - Bar-Gil Shitrit A
AD  - Digestive Diseases Institute, Shaare Zedek Medical Center, 12 Bayit St., 91031, 
      Jerusalem, Israel.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
DEP - 20190228
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Immunosuppressive Agents)
RN  - E7WED276I5 (Mercaptopurine)
SB  - IM
MH  - Adult
MH  - Anemia/*chemically induced
MH  - Anemia, Neonatal/chemically induced
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/*therapeutic use
MH  - Infant
MH  - Infant, Newborn
MH  - Inflammatory Bowel Diseases/*drug therapy
MH  - Mercaptopurine/administration & dosage/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/*drug therapy
MH  - Pregnancy Outcome
OTO - NOTNLM
OT  - Anemia
OT  - Hemoglobin
OT  - Inflammatory bowel disease
OT  - Pregnancy
OT  - Thiopurine
EDAT- 2019/03/01 06:00
MHDA- 2020/02/08 06:00
CRDT- 2019/03/01 06:00
PHST- 2018/09/05 00:00 [received]
PHST- 2019/02/20 00:00 [accepted]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2020/02/08 06:00 [medline]
PHST- 2019/03/01 06:00 [entrez]
AID - 10.1007/s10620-019-05555-0 [pii]
AID - 10.1007/s10620-019-05555-0 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2019 Aug;64(8):2286-2290. doi: 10.1007/s10620-019-05555-0. Epub 2019 
      Feb 28.